Increased functional cell surface expression of CFTR and ΔF508-CFTR by the anthracycline doxorubicin

Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, New Hampshire 03755-3835, USA.
AJP Cell Physiology (Impact Factor: 3.78). 06/2001; 280(5):C1031-7.
Source: PubMed


Cystic fibrosis (CF) is a disease that is caused by mutations within the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The most common mutation, DeltaF508, accounts for 70% of all CF alleles and results in a protein that is defective in folding and trafficking to the cell surface. However, DeltaF508-CFTR is functional when properly localized. We report that a single, noncytotoxic dose of the anthracycline doxorubicin (Dox, 0.25 microM) significantly increased total cellular CFTR protein expression, cell surface CFTR protein expression, and CFTR-associated chloride secretion in cultured T84 epithelial cells. Dox treatment also increased DeltaF508-CFTR cell surface expression and DeltaF508-CFTR-associated chloride secretion in stably transfected Madin-Darby canine kidney cells. These results suggest that anthracycline analogs may be useful for the clinical treatment of CF.

5 Reads
  • Source
    • "The underlying reasons for mitomycin C-induced effects of MRP 1 and 3 could also be derived from findings on maturation and trafficking of MDR proteins.50 For example, Maitra et al observed a distinct increase of membrane p-glycoprotein directly after a 4-hour incubation time with mitomycin C.50 At the same time, the total p-glycoprotein level remained constant, and a decrease was not observed until 12 to 24 hours thereafter. In a similar way, mitomycin C could also have induced a redistribution of intracellular MDR protein storage pools which were not detectable in our study, since the incubation times employed were too long (24 hours) and MRP expression analyses were started immediately after finalization of treatments. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The presence of multidrug resistance-associated protein (MRP) in cancer cells is known to be responsible for many therapeutic failures in current oncological treatments. Here, we show that the combination of different effectors like hyperthermia, iron oxide nanoparticles, and chemotherapeutics influences expression of MRP 1 and 3 in an adenocarcinoma cell line. BT-474 cells were treated with magnetic nanoparticles (MNP; 1.5 to 150 μg Fe/cm(2)) or mitomycin C (up to 1.5 μg/cm(2), 24 hours) in the presence or absence of hyperthermia (43°C, 15 to 120 minutes). Moreover, cells were also sequentially exposed to these effectors (MNP, hyperthermia, and mitomycin C). After cell harvesting, mRNA was extracted and analyzed via reverse transcription polymerase chain reaction. Additionally, membrane protein was isolated and analyzed via sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting. When cells were exposed to the effectors alone or to combinations thereof, no effects on MRP 1 and 3 mRNA expression were observed. In contrast, membrane protein expression was influenced in a selective manner. The effects on MRP 3 expression were less pronounced compared with MRP 1. Treatment with mitomycin C decreased MRP expression at high concentrations and hyperthermia intensified these effects. In contrast, the presence of MNP only increased MRP 1 and 3 expression, and hyperthermia reversed these effects. When combining hyperthermia, magnetic nanoparticles, and mitomycin C, no further suppression of MRP expression was observed in comparison with the respective dual treatment modalities. The different MRP 1 and 3 expression levels are not associated with de novo mRNA expression, but rather with an altered translocation of MRP 1 and 3 to the cell membrane as a result of reactive oxygen species production, and with shifting of intracellular MRP storage pools, changes in membrane fluidity, etc, at the protein level. Our results could be used to develop new treatment strategies by repressing mechanisms that actively export drugs from the target cell, thereby improving the therapeutic outcome in oncology.
    International Journal of Nanomedicine 01/2013; 8:351-63. DOI:10.2147/IJN.S37465 · 4.38 Impact Factor

  • The Lancet 01/2002; 358(9298):2014-6. DOI:10.1016/S0140-6736(01)07138-0 · 45.22 Impact Factor
  • Source

    The Lancet 01/2002; 358(9298):2014. DOI:10.1016/S0140-6736(01)07137-9 · 45.22 Impact Factor
Show more

Similar Publications